GeNeuro (EPA: GNRO.PA) is a Swiss pharmaceutical company focused on the treatment of autoimmune diseases mediated by the pathogenic expression of human endogenous retroviral (HERV) elements. The envelope protein of the multiple sclerosis-associated retrovirus (MSRV), while normally silent, is ubiquitously expressed in MS lesions and, as an activator of the innate immune system, has been proposed to be the causal trigger underlying MS pathology. GeNeuro is currently evaluating GNbAC1, an antibody against MSRV-Env, in a Phase IIb study in collaboration with their partner Servier and expects to report preliminary results in the fourth quarter of 2017. In addition, GeNeuro has a broad portfolio of antibodies to address HERVs that have been linked to other human diseases.

Read More